治疗急性缺血性卒中新药:依达拉奉右莰醇  

A new drug for treatment of acute ischemic stroke: edaravone-dexborneol

作　　者：段宝京 方灵芝[1] 关丽叶 李晓明[1] 董占军[1] DUAN Bao-jing;FANG Ling-zhi;GUAN Li-ye;LI Xiao-ming;DONG Zhan-jun(Department of Pharmacy,Hebei General Hospital,Shijiazhuang HEBEI 050051,China)

机构地区：[1]河北省人民医院药学部,河北石家庄050051

出　　处：《中国新药与临床杂志》2022年第10期588-593,共6页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：依达拉奉右莰醇为先声药业自主研发的国家1类新药,是治疗缺血性卒中的新型神经保护剂。依达拉奉右莰醇中依达拉奉和右莰醇两种活性成份以4 1的配比组合。依达拉奉是自由基清除剂,右莰醇可调节血脑屏障通透性,增加依达拉奉在脑组织中浓度,两者协同发挥清除自由基、抗炎、保护血脑屏障等多重作用。临床试验表明与依达拉奉相比,依达拉奉右莰醇在疗效方面更有优势,且安全性相当。Edaravone-dexborneol, a national class 1 new drug independently developed by Simcere Pharmaceuticals, is a new neuroprotective agent for the treatment of ischemic stroke. Edaravone-dexborneol contains two active ingredients of edaravone and dexborneol with a ratio of 4 1. Edaravone is a free radical scavenger and dexborneol can regulate the permeability of the blood brain barrier and increase the concentration of edaravone in the brain, so edaravone-dexborneol can synergistically play multiple roles such as scavenging free radicals, anti-inflammatory, and protecting the blood brain barrier. Clinical trials have shown that compared with edaravone, edaravone-dexborneol has more advantages in efficacy, and its safety is equivalent to edaravone.

关 键 词：依达拉奉 右莰醇 缺血性卒中 临床研究 

分 类 号：R971[医药卫生—药品]